FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296710287> ?p ?o ?g. }

• W4296710287 abstract "<h3>Background</h3> We recently discovered recurrent cathepsin S (CTSS) alterations, i.e., either somatic gain-of-function mutations (at the hotspot Y132) or amplification/overexpression of CTSS that result in aberrant hyperactivity of this lysosomal cysteine protease and promote tumor growth in follicular lymphoma (FL). In addition, CTSS is frequently overexpressed in other lymphomas and other cancers (e.g., Glioma, triple-negative breast cancer, renal cancer). Intriguingly, when released from the lysosome, CTSS is tightly linked with the regulation of cell death pathways. <h3>Materials and Methods</h3> BH3 profiling allows determining, to what extent a cell is primed towards cell death. It measures the extent of mitochondrial membrane permeabilization (MOMP) in response to BH3 peptides. Thus, BH3 profiling can record the net response of the pro- and anti-apoptotic interactions of the >15 apoptotic BCL2 family members in high-throughput (384-well plate flow-cytometry). Using BH3 profiling, we aimed to exploit the therapeutic vulnerabilities of CTSS hyperactive tumors, with a focus on compounds that induce lysosomal membrane permeabilization (LMP). <h3>Results</h3> Our preliminary data suggest that LMP is a promising novel therapeutic strategy in tumors with CTSS hyperactivity. Specifically, dose-response curves for cell viability indicated a higher sensitivity to LLOMe treatment in DG75 CTSS knock-out (CTSS^KO) lymphoma cells with re-expression of CTSS WT (KO+CTSS^WT), and highest sensitivity in DG75 with overexpression of CTSS Y132D (KO+CTSS^Y132D). Similar results were obtained in single-cell derived clones from Karpas422 lymphoma cells (CTSS KO vs WT vs Y132D). Release of cathepsins into the cytosol can lead to MOMP and apoptosis through the cleavage of BCL2 family members, including proteolytic inactivation of anti-apoptotic MCL1 and cleavage of BID which produces proapoptotic truncated BID (tBID). Of note, CTSS is the only cathepsin that remains enzymatically active at neutral pH for hours. Western blot confirmed increased cleavage of BID, MCL-1 and PARP-1 in LLOMe treated CTSS^WT and CTSS^Y132D-cells, indicating that CTSS release by LMP can more efficiently induce apoptosis in CTSS hyperactive lymphomas. BH3 profiling confirmed that CTSS hyperactivity is associated with a dependency on MCL-1 and BCL-2 following LMP. In addition, CTSS hyperactive glioblastoma cell lines U-87 and U-251 also showed MCL-1 dependency following LMP, indicating that cytosolic CTSS hyperactivity primes for MCL-1 dependency across many cancer types. <h3>Conclusions</h3> Releasing CTSS from the lysosome is novel, attractive concept that can be combined with conventional, apoptosis-inducing therapies. <h3>Disclosure Information</h3> <b>J. Hildebrand:</b> None. <b>P. Rengasayee:</b> None. <b>M. Antoniolli:</b> None. <b>L. Hackett:</b> None. <b>L. Adolph:</b> None. <b>S. Häbe:</b> None. <b>M. Heide:</b> None. <b>S. Wilhelm:</b> None. <b>C. Ludwig:</b> None. <b>C. Strobl:</b> None. <b>V. Passerini:</b> None. <b>M. Bergwelt-Baildon:</b> None. <b>R. Koch:</b> None. <b>M. Davids:</b> None. <b>O. Weigert:</b> None." @default.
• W4296710287 created "2022-09-23" @default.
• W4296710287 creator A5002283609 @default.
• W4296710287 creator A5011695051 @default.
• W4296710287 creator A5017861385 @default.
• W4296710287 creator A5018834596 @default.
• W4296710287 creator A5021727093 @default.
• W4296710287 creator A5024016911 @default.
• W4296710287 creator A5025684781 @default.
• W4296710287 creator A5026024962 @default.
• W4296710287 creator A5047291404 @default.
• W4296710287 creator A5048714300 @default.
• W4296710287 creator A5050292033 @default.
• W4296710287 creator A5054167084 @default.
• W4296710287 creator A5063050270 @default.
• W4296710287 creator A5077450032 @default.
• W4296710287 creator A5080723417 @default.
• W4296710287 date "2022-09-01" @default.
• W4296710287 modified "2023-09-26" @default.
• W4296710287 title "P09.05 Exploring the therapeutic vulnerabilities of cathepsin S hyperactive tumors" @default.
• W4296710287 doi "https://doi.org/10.1136/jitc-2022-itoc9.61" @default.
• W4296710287 hasPublicationYear "2022" @default.
• W4296710287 type Work @default.
• W4296710287 citedByCount "0" @default.
• W4296710287 crossrefType "proceedings-article" @default.
• W4296710287 hasAuthorship W4296710287A5002283609 @default.
• W4296710287 hasAuthorship W4296710287A5011695051 @default.
• W4296710287 hasAuthorship W4296710287A5017861385 @default.
• W4296710287 hasAuthorship W4296710287A5018834596 @default.
• W4296710287 hasAuthorship W4296710287A5021727093 @default.
• W4296710287 hasAuthorship W4296710287A5024016911 @default.
• W4296710287 hasAuthorship W4296710287A5025684781 @default.
• W4296710287 hasAuthorship W4296710287A5026024962 @default.
• W4296710287 hasAuthorship W4296710287A5047291404 @default.
• W4296710287 hasAuthorship W4296710287A5048714300 @default.
• W4296710287 hasAuthorship W4296710287A5050292033 @default.
• W4296710287 hasAuthorship W4296710287A5054167084 @default.
• W4296710287 hasAuthorship W4296710287A5063050270 @default.
• W4296710287 hasAuthorship W4296710287A5077450032 @default.
• W4296710287 hasAuthorship W4296710287A5080723417 @default.
• W4296710287 hasBestOaLocation W42967102871 @default.
• W4296710287 hasConcept C151701858 @default.
• W4296710287 hasConcept C153911025 @default.
• W4296710287 hasConcept C181199279 @default.
• W4296710287 hasConcept C185592680 @default.
• W4296710287 hasConcept C190283241 @default.
• W4296710287 hasConcept C28021979 @default.
• W4296710287 hasConcept C31573885 @default.
• W4296710287 hasConcept C502942594 @default.
• W4296710287 hasConcept C54355233 @default.
• W4296710287 hasConcept C553184892 @default.
• W4296710287 hasConcept C55493867 @default.
• W4296710287 hasConcept C81885089 @default.
• W4296710287 hasConcept C86803240 @default.
• W4296710287 hasConcept C95444343 @default.
• W4296710287 hasConceptScore W4296710287C151701858 @default.
• W4296710287 hasConceptScore W4296710287C153911025 @default.
• W4296710287 hasConceptScore W4296710287C181199279 @default.
• W4296710287 hasConceptScore W4296710287C185592680 @default.
• W4296710287 hasConceptScore W4296710287C190283241 @default.
• W4296710287 hasConceptScore W4296710287C28021979 @default.
• W4296710287 hasConceptScore W4296710287C31573885 @default.
• W4296710287 hasConceptScore W4296710287C502942594 @default.
• W4296710287 hasConceptScore W4296710287C54355233 @default.
• W4296710287 hasConceptScore W4296710287C553184892 @default.
• W4296710287 hasConceptScore W4296710287C55493867 @default.
• W4296710287 hasConceptScore W4296710287C81885089 @default.
• W4296710287 hasConceptScore W4296710287C86803240 @default.
• W4296710287 hasConceptScore W4296710287C95444343 @default.
• W4296710287 hasLocation W42967102871 @default.
• W4296710287 hasOpenAccess W4296710287 @default.
• W4296710287 hasPrimaryLocation W42967102871 @default.
• W4296710287 hasRelatedWork W1529578025 @default.
• W4296710287 hasRelatedWork W1987695408 @default.
• W4296710287 hasRelatedWork W2003720298 @default.
• W4296710287 hasRelatedWork W2053279347 @default.
• W4296710287 hasRelatedWork W2067038367 @default.
• W4296710287 hasRelatedWork W2106564520 @default.
• W4296710287 hasRelatedWork W2151098840 @default.
• W4296710287 hasRelatedWork W2328524531 @default.
• W4296710287 hasRelatedWork W2403432132 @default.
• W4296710287 hasRelatedWork W4283693058 @default.
• W4296710287 isParatext "false" @default.
• W4296710287 isRetracted "false" @default.
• W4296710287 workType "article" @default.